Publicly-traded company Strongbridge Biopharma plc (NASDAQ:SBBP) had a closing price of $1.59 yesterday. Meanwhile, the average 12-month price target from Wall Street analysts is currently $13.57, this means that the stock is underpriced by 88.28%. In the past 52 weeks the company’s stock price has moved within the range of $1.87 to $6.05.
This particular stock’s 5-day moving average is 2.12, its 20-day moving average is 2.05 and its 100-day moving average is 2.59. Strongbridge Biopharma plc (SBBP) currently has 50.17M shares outstanding, which means that its market capitalization is $79.77M.
The Details: Strongbridge Biopharma plc (SBBP) Financial Health
Return on Assets, which is expressed as a percentage, tells us how well a public company is using its assets to turn a profit. The larger the percentage, the better it is At the moment, Strongbridge Biopharma plc Return on Assets is 24.60%.
What Does Wall Street Say about Company?
When selecting potential stocks to buy, many investors want to find out what Wall Street professionals are thinking about the company beforehand – like what the average analyst rating is. At the moment, the average analyst rating for SBBP is Buy. Out of 7 total analysts who were surveyed, 0 rated it a sell, 0 rated it a underweight, 0 rated it an overweight, 0 rated it hold, and 7 rated it a Buy.
Understanding Profitability at Strongbridge Biopharma plc (SBBP)
A good way of assessing a public company’s profitability is by looking at its Earnings per Share (EPS). In the most recent financial results released by Strongbridge Biopharma plc, for the quarter ending on 09/2019, the company posted EPS of -0.32. The average estimate of Wall Street analysts had projected -0.30.
Wall Street analysts, on average, are forecasting the company’s EPS to be -0.27, compared to -0.44 reported in the same quarter last year. When it comes to net revenue, the average estimate from a total of 6 analysts is 4.96M – compared to 5.35M posted in the year-ago period.